stockrowZymeworks Inc.
ZYME Healthcare Biotechnology
Zymeworks Inc.’s revenue for fiscal 2025 (year ended December 2025) was $106.0 million, up 38.9% from fiscal 2024.
- Revenue
- −90.6%
- EPS
- −2,166.7%
- Free cash flow
- −385.5%
Quarter to June 2026, against a year earlier
Follow ZYME
Alert me
Zymeworks Inc. (ZYME) Return on equity
Zymeworks Inc.'s return on equity over the twelve months to 30 June 2026 was −72.3%, down 45.6 percentage points from fiscal 2025 (−26.7%). Over the past ten years it has ranged from −248.2% (fiscal 2016) to 33.5% (fiscal 2022); the current reading is higher than 64% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −26.7% | 3.82 |
| FY2024 | −30.5% | (5.76) |
| FY2023 | −24.8% | (58.29) |
| FY2022 | 33.5% | 97.80 |
| FY2021 | −64.3% | (9.21) |
| FY2020 | −55.1% | 13.17 |
| FY2019 | −68.3% | (43.63) |
| FY2018 | −24.6% | (7.20) |
| FY2017 | −17.4% | 230.80 |
| FY2016 | −248.2% | (107.48) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| BHVN Biohaven Ltd. compare | 940.5% |
| AUPH Aurinia Pharmaceuticals Inc compare | 61.4% |
| VCEL Vericel Corporation compare | 9.44% |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.00% |
| COAG Hemab Therapeutics Holdings, Inc. compare | 0.00% |
| SEPN Septerna, Inc. compare | −6.34% |
| IMNM Immunome, Inc. compare | −64.0% |
| ZYME Zymeworks Inc. | −72.3% |
| VERA Vera Therapeutics, Inc. compare | −91.8% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ZYME
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement